Question

Peripheral smear shows sickle-shaped RBCs in a known case of sickle cell disease. Which of the following is the best drug for disease modification?

• A. Voxelotor
• B. Hydroxyurea
• C. Crizanlizumab
• D. L-glutamine

Hint:

Understand the distinct mechanisms of SCD drugs:
Hydroxyurea: Increases HbF.
Voxelotor: Increases Hb-O$_2$ affinity, preventing HbS polymerization.
Crizanlizumab: Blocks P-selectin, preventing vaso-adhesion.
L-glutamine: Antioxidant, reduces RBC membrane damage.

Answer 1

The Correct Option is A

Concept:
The clinical scenario presents a patient with Sickle Cell Disease (SCD) demonstrating active sickling on a peripheral smear.
The question asks for the best drug for disease modification specifically targeting the presence of sickle-shaped RBCs.
Explanation:
• Sickle Cell Disease is caused by a point mutation in the beta-globin gene resulting in hemoglobin S (HbS).

• Under deoxygenated conditions, HbS polymerizes, distorting the red blood cell into a rigid, sickle shape.

• These sickled cells undergo premature hemolysis and cause vaso-occlusion, leading to the hallmark complications of SCD.

• While Hydroxyurea has long been the primary disease-modifying agent (it works indirectly by inducing the production of fetal hemoglobin (HbF), which dilutes HbS and prevents polymerization), Voxelotor offers a novel, direct mechanism against the sickling process itself.

• Voxelotor is a first-in-class hemoglobin oxygen-affinity modulator.

• It binds reversibly to the N-terminal valine of the alpha chain of hemoglobin.

• By doing so, it stabilizes the oxygenated state of hemoglobin (shifting the oxygen dissociation curve to the left).

• Because HbS only polymerizes in its deoxygenated state, keeping hemoglobin oxygenated directly prevents the root cause of sickling.

• Clinical trials have shown that Voxelotor significantly reduces hemolysis, raises total hemoglobin levels, and decreases the number of irreversibly sickled cells on the peripheral smear.

• Given that the question specifically highlights the active presence of sickle-shaped RBCs on the smear, Voxelotor is precisely targeted to disrupt this exact morphological transformation.

• Crizanlizumab is a P-selectin inhibitor that reduces vaso-occlusive crises by preventing cell adhesion to the endothelium, but it does not stop the RBCs from sickling.

• L-glutamine reduces oxidative stress in RBCs but is less potent for direct morphological reversal compared to Voxelotor.
Final answer:
Voxelotor is a direct anti-sickling agent and the best choice in this specific context to reverse the red cell morphology.